Literature DB >> 24802730

Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes.

Joanna Nazim1, Wojciech Fendler, Jerzy Starzyk.   

Abstract

INTRODUCTION: To assess in a prospective study the course and the predictors of microalbuminuria in children and adolescents with type 1 diabetes.
MATERIAL AND METHODS: 438 children and adolescents who developed diabetes in the years 1985-2004 were followed for 9.2 ± 3.4 years from the diagnosis. Microalbuminuria was assessed on the basis of timed overnight urine collections performed once per year. Variability of glycated haemoglobin was expressed as a coefficient of variation (%) calculated by dividing standard deviation (adjusted for the number of measurements) by mean of HbA1c.
RESULTS: Microalbuminuria was noted in 99 patients (22.6%) after 8.27 ± 3.3 years of diabetes. In 29 individuals (6.6%), microalbuminuria was persistent. The prevalence of microalbuminuria was not dependent on the period of diabetes diagnosis. During followup, 17 (58.6%) patients with persistent MA reverted to normoalbuminuria. Children without any episodes of microalbuminuria had significantly lower HbA1c variability (8.44%; 95% CI 7.81-9.08%) than those with one (10.28% 95% CI 9.10-11.47%; p = 0.007). The difference of HbA1c variability between patients with and without microalbuminuria persisted after correction by mean HbA1c (p = 0.04). Risk factors for ever developing microalbuminuria during the observation period in multivariate analysis included: mean HbA1c (HR [95% CI]: 1.17 [1.00-1.37; p = 0.05]) and its variability (1.04 [1.00-1.07]; p = 0.05), insulin dose (HR per 0.1 unit*kg- 1*day-1: 0.87 [0.79-0.96]; p = 0.005), presence of arterial hypertension (1.63 [1.07-2.49]; p = 0.02), and age at onset of diabetes (1.15 [1.08-1.21]; p < 0.0001).
CONCLUSIONS: Children who develop microalbuminuria are characterised by poorer and more variable metabolic control, hinting at the importance of interventions aimed at both improvement and stabilisation of HbA1c levels.

Entities:  

Mesh:

Year:  2014        PMID: 24802730     DOI: 10.5603/EP.2014.0012

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  6 in total

1.  Association between visit-to-visit variability of HbA1c and cognitive decline: a pooled analysis of two prospective population-based cohorts.

Authors:  Zhe-Bin Yu; Yao Zhu; Die Li; Meng-Yin Wu; Meng-Ling Tang; Jian-Bing Wang; Kun Chen
Journal:  Diabetologia       Date:  2019-09-04       Impact factor: 10.122

2.  Disordered Eating Behaviors Are Not Increased by an Intervention to Improve Diet Quality but Are Associated With Poorer Glycemic Control Among Youth With Type 1 Diabetes.

Authors:  Miriam H Eisenberg Colman; Virginia M Quick; Leah M Lipsky; Katherine W Dempster; Aiyi Liu; Lori M B Laffel; Sanjeev N Mehta; Tonja R Nansel
Journal:  Diabetes Care       Date:  2018-01-25       Impact factor: 19.112

Review 3.  Glucose variability, HbA1c and microvascular complications.

Authors:  Jan Škrha; Jan Šoupal; Jan Škrha; Martin Prázný
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

4.  All Components of Metabolic Syndrome Are Associated with Microalbuminuria in a Chinese Population.

Authors:  Yi-Yen Lee; Chih-Kai Yang; Yi-Ming Weng; Chung-Hsun Chuang; Wei Yu; Jih-Chang Chen; Wen-Cheng Li
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

5.  HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment.

Authors:  Emma S Scott; Rachel T McGrath; Andrzej S Januszewski; Daniel Calandro; Anandwardhan A Hardikar; David N O'Neal; Gregory Fulcher; Alicia J Jenkins
Journal:  BMJ Open       Date:  2019-12-29       Impact factor: 2.692

6.  The Effect of HbA1c Variability as a Risk Measure for Microangiopathy in Type 1 Diabetes Mellitus.

Authors:  Pedro Romero-Aroca; Raul Navarro-Gil; Albert Feliu; Aida Valls; Antonio Moreno; Marc Baget-Bernaldiz
Journal:  Diagnostics (Basel)       Date:  2021-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.